GFH009 Receives FDA Fast Track, Orphan Drug Designations for Treating R/R Peripheral T-cell Lymphomas and Acute Myeloid Leukemia

GenFleet Therapeutics announced that the FDA has granted another two designations for SLS009 (GFH009). GFH009 so far has received both Fast Track Designation and Orphan Drug Designation for the treatment of adult patients with relapsed/refractory peripheral T cell lymphomas and r/r acute myeloid leukemia.